<DOC>
	<DOCNO>NCT00006695</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate cancer cell either kill deliver cancer-killing substance without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase II trial study well monoclonal antibody therapy , chemotherapy , peripheral stem cell transplant work treat patient relapsed refractory non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Monoclonal Antibody Therapy , Combination Chemotherapy , Peripheral Stem Cell Transplant Treating Patients With Relapsed Refractory Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare response rate time treatment failure patient relapse refractory non-Hodgkin 's lymphoma treat iodine I 131 monoclonal antibody anti-B1 , follow high-dose carmustine , etoposide , cytarabine , melphalan ( BEAM ) , autologous peripheral blood stem cell transplantation ( APBSCT ) v historical control patient treat high-dose BEAM carmustine , etoposide , cytarabine , cyclophosphamide APBSCT . - Determine safety regimen patient . OUTLINE : Autologous peripheral blood stem cell ( PBSC ) harvest select CD34+ cell granulocyte macrophage colony-forming unit . On day -19 , patient receive unlabeled monoclonal antibody anti-B1 ( MOAB anti-B1 ) IV follow dosimetric dose iodine I 131 MOAB anti-B1 IV 20 minute . On day -12 , patient receive unlabeled MOAB anti-B1 IV follow therapeutic dose iodine I 131 MOAB anti-B1 IV 20 minute . Patients receive high-dose chemotherapy comprise carmustine IV day -6 , etoposide IV cytarabine IV twice daily day -5 -2 , melphalan IV day -1 . Patients undergo autologous PBSC transplantation day 0 . Patients follow day 30 100 , 6 month , annually thereafter . PROJECTED ACCRUAL : A total 50 patient accrue study 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Iodine-131 anti-B1 antibody</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Cadexomer iodine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonHodgkin 's lymphoma ( NHL ) one follow type : Diffuse large Bcell Composite ( least 50 % tumor show diffuse histology ) Diffuse mixed cell Immunoblastic Relapsed refractory disease sensitive initial subsequent conventional therapy ( least partial response ) Eligible highdose carmustine , etoposide , cytarabine , melphalan protocol autologous bone marrow transplantation peripheral blood stem cell transplantation Evidence CD20 antigen expression tumor tissue Bidimensionally measurable disease No progressive disease field previously irradiate 3,500 cGy within past year Adequate peripheral blood stem cell At least 15,000,000 CD34+ cells/kg OR At least 25,000 granulocyte macrophage colonyforming units/kg No known brain leptomeningeal metastasis PATIENT CHARACTERISTICS : Age : 19 70 Performance status : Karnofsky 70100 % Life expectancy : At least 4 month posttransplantation Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 2.0 mg/dL Renal : Creatinine le 2.0 mg/dL No active obstructive hydronephrosis Cardiovascular : Cardiac ejection fraction least 40 % follow criterion : Age 60 Significant cardiac history ( myocardial infarction congestive heart failure ) Received great 350 mg/m^2 prior doxorubicin No New York Heart Association class III IV heart disease Pulmonary : DLCO least 50 % predict Other : No evidence severe organ dysfunction No major medical illnesses No active infection require IV antibiotic No malignancy within past 5 year except adequately treated skin cancer carcinoma situ cervix HIV negative Not pregnant Negative pregnancy test Fertile patient must use effective contraception least 6 month study participation Human antimouse antibody negative No vulnerability PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No prior peripheral blood stem cell transplantation follow highdose chemotherapy chemoradiotherapy At least 4 week since prior biologic therapy recover No concurrent biologic therapy NHL Chemotherapy : See Disease Characteristics See Biologic therapy At least 4 week since prior cytotoxic chemotherapy recover No concurrent chemotherapy antineoplastic therapy NHL Endocrine therapy : No concurrent steroid except maintenancedose steroid noncancerous disease Radiotherapy : See Disease Characteristics See Biologic therapy At least 4 week since prior radiotherapy recover No concurrent external beam radiotherapy NHL Surgery : Not specify Other : At least 4 week since prior immunosuppressant recover No concurrent participation protocol involve nonFDAapproved drug biologics</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
</DOC>